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The findings reported by Jones et al. 
are of importance when considering the 
optimal therapeutic strategy to initiate 
in a given patient with CTCL. Because 
methylation of the Fas promoter is not 
observed in all patients with SzS, the use 
of hypomethylating drugs may not be 
equally effective in restoring sensitivity 
to Fas-mediated apoptosis in all patients. 
Thus, not only is the existence of potent 
hypomethylating agents important, but 
their use will require a “personalized” 
medical approach in which these agents 
are employed in patients having tumors 
with positional methylation of the Fas 
CpG island.
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How Does Intramolecular Epitope 
Spreading Occur in BPAG2 (BP180)?
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Tadashi Karashima1, Takekuni Nakama1 and Shinichiro Yasumoto1
Several studies have suggested that autoantibodies directed against multiple 
epitopes occur via epitope spreading in autoimmune bullous skin diseases. 
However, the precise sequence of events in epitope spreading has not been elu-
cidated for any of the epidermal autoantigens. In this issue, using a transgenic 
mouse model, Di Zenzo et al. report that intramolecular epitope spreading does 
occur for human BPAG2.
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In order to investigate the mechanism 
of epitope spreading for BPAG2 (BP180 
or type XVII collagen), Di Zenzo et al. 
(2010, this issue) performed a sophis-
ticated set of experiments using trans-
genic mice harboring human BPAG2. 
To immunize mice with human BPAG2, 
skin samples from transgenic mice that 
expressed human BPAG2 were grafted 
onto syngeneic mice. Sequential serum 
samples were then obtained from 
the immunized mice, and antibodies 
against human BPAG2 were detected 
by an enzyme-linked immunosorbent 
assay using recombinant proteins for 
four intracellular domains (ICDs) and 
three extracellular domains (ECDs) 
of human BPAG2. Most grafted mice 
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initially developed anti-BPAG2 anti-
bodies directed against ECD epitopes. 
Subsequently, some of the mice devel-
oped antibodies to additional ECD 
epitopes and to ICD epitopes. In general, 
the titers of antibodies against the ECD 
epitopes were high, whereas antibodies 
against the ICD epitopes were low, and 
they were detectable for shorter peri-
ods of time. An interesting observation 
was that the development of antibodies 
against ICD epitopes correlated with 
graft loss, but rejection occurred by an 
unknown mechanism. Thus, Di Zenzo 
et al. confirmed successfully and direct-
ly that epitope spreading does occur in 
this animal model of an autoimmune 
bullous skin disease.
multiple epitopes occur in the 
autoantigens that characterize 
autoimmune bullous diseases
Epitope spreading has been shown to 
occur in several autoimmune bullous skin 
diseases (Chan et al., 1998). The multiple 
epitopes on desmoglein 1 (Dsg1) or Dsg3 
are targets of antibodies found in sera 
from patients with pemphigus vulgaris, 
pemphigus foliaceus, and paraneoplas-
tic pemphigus as determined by ELISA 
assays using domain-swapped molecules 
between human Dsg1 and Dsg3 (Futei et 
al., 2003). Recently, these results were 
confirmed in an ELISA assay using newly 
elaborated domain-swapped molecules 
of human Dsg1 and Dsg3 against the 
human Dsg2 backbone (Chan et al., in 
press; B Ohyama et al., personal commu-
nication). Previously, we demonstrated 
that paraneoplastic pemphigus sera had 
autoantibodies against multiple epitopes 
in human envoplakin and periplakin, 
two major autoantigens found in para-
neoplastic pemphigus, as demonstrated 
by an ELISA assay, using bacterial recom-
binant proteins from various domains 
of envoplakin and periplakin (Nagata et 
al., 2001). We showed that bullous pem-
phigoid sera had autoantibodies against 
multiple epitopes in the various domains 
of human BPAG1 (BP230), particularly 
to the C-terminal globular domain, by 
immunoblot analysis using bacterial 
recombinant proteins of various domains 
of human BPAG1 (Hamada et al., 2001). 
We also showed that anti-basement 
membrane zone antibodies in the sera 
of patients with epidermolysis bullosa 
acquisita reacted with distinct epitopes 
in the NC1 domain, the central collag-
enous domain, and the NC2 domain 
by immunoblot analysis using bacte-
rial recombinant proteins from selected 
domains of human type VII collagen 
and immunoelectron microscopy (Ishii 
et al., 2004).
These studies strongly suggest that 
intramolecular epitope spreading occurs 
in several autoimmune bullous skin 
diseases. Although the previous studies 
detected autoantibodies against multiple 
epitopes, no study detailed the sequen-
tial development of autoantibodies to 
different epitopes over time. Di Zenzo et 
al. (2010) have now shown that epitope 
spreading actually takes place. They 
found that mice immunized against 
human BPAG2 occasionally developed 
autoantibodies against some epitopes 
present in the ICD of BPAG2, although 
such autoantibodies appeared late and 
were less persistent. Interestingly, we 
found that pemphigus patients some-
times have autoantibodies that react 
against the ICD of Dsg1 and Dsg3 
(Ohata et al., 2001). Thus, the study by 
Di Zenzo et al. also confirms that anti-
bodies against the ICD of transmembra-
nous antigens can occur in autoimmune 
bullous skin diseases, probably also by 
epitope-spreading mechanisms. The 
mechanism by which such antibodies 
develop remains unknown.
BPaG2 is the most suitable autoantigen for 
studying mechanisms of epitope spreading
Autoantibodies to distinct epitopes 
within BPAG2 develop in a variety of 
autoimmune subepidermal bullous skin 
diseases. First, anti-basement mem-
brane zone autoantibodies in both 
bullous pemphigoid and herpes gesta-
tionis were reported to preferentially 
react with the NC16a domain of BPAG2 
(Matsumura et al., 1996). In addition, 
IgG and IgA antibodies in anti-BP180 
type mucous membrane pemphig-
oid have been shown to react with the 
C-terminal domain of BPAG2 (Nie and 
Hashimoto, 1999). Furthermore, we 
showed that IgA antibodies in lamina 
lucida–type linear IgA bullous derma-
tosis reacted with epitope(s) within 
the fifteenth collagenous domain of 
BPAG2, which is hidden in the intact 
180-kDa BPAG2 molecule (Nie et al., 
2000). For these reasons, BPAG2 is 
considered the most suitable antigen 
with which to elucidate mechanisms 
of epitope spreading in autoimmune 
bullous skin diseases. Figure 1 shows 
representative immunoblot analyses for 
three antigen sources used routinely in 
our laboratory.
Figure 1. representative results of immunoblot analyses for BPaG2 (BP180) using three different 
antigen sources. (a) Bacterial recombinant protein of the NC16a domain of BPAG2. IgG antibodies in 
bullous pemphigoid (BP) sera reacted with this recombinant protein (RP). (b) Bacterial recombinant 
protein of C-terminal domain of BPAG2. IgG antibodies in anti-BP180-type mucous membrane 
pemphigoid (MMP) sera reacted with this RP. The upper protein band marked with an asterisk indicates 
nonspecific reactivity because it is also shown by normal controls. (c) Concentrated supernatant sample 
from cultured HaCaT cells. IgA antibodies in lamina lucida type of linear IgA bullous dermatosis (LAD) 
sera reacted with the 120-kDa LAD-1 antigen.
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Perspectives
Although Di Zenzo et al. (2010) demon-
strated convincingly that intramolecular 
epitope spreading occurs in BPAG2, 
many questions remain. The first is why 
patients with bullous pemphigoid pref-
erentially develop IgG autoantibod-
ies to epitopes on the NC16a domain 
of BPAG2. Second, why do autoanti-
bodies in bullous pemphigoid react 
with epitopes in the NC16a domain 
of BPAG2, whereas autoantibodies in 
anti-BP180–type mucous membrane 
pemphigoid react with epitopes in the 
C-terminal domain? More important, 
how do the antibodies directed against 
these distinct domains of BPAG2 result 
in different clinical features (i.e., large, 
tense skin blisters in bullous pemphig-
oid and predominant erosive mucosal 
lesions in anti-BP180-type mucous 
membrane pemphigoid)? Why do IgA 
antibodies in lamina lucida–type lin-
ear IgA bullous dermatosis react with 
specific epitopes in 120- and 97-kDa 
linear IgA bullous dermatosis (LAD)-1 
antigens produced from 180-kDa intact 
BPAG2 by proteolytic processing (Nie 
et al., 2000)? Future studies should 
unravel the mechanisms by which the 
hidden epitope in intact 180-kDa mol-
ecule (intact BPAG2) is exposed in 
linear IgA bullous dermatosis to autoan-
tibodies against the 120- and 97-kDa 
LAD-1 antigens.
Finally, and perhaps most important, 
we do not know yet why the develop-
ment of antibodies against ICD epitopes 
in human BPAG2 correlated with skin-
graft loss. The relevance of this phenom-
enon to autoimmune bullous diseases 
remains to be determined.
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More or Less: Copy Number 
Alterations in Mycosis Fungoides
William M. Lin1 and Michael Girardi1
mycosis fungoides (mF) is the most common form of cutaneous t-cell lymphoma 
(ctcL), a heterogeneous group of non-Hodgkin’s lymphomas of skin-homing 
t cells. mF may vary from limited patchy skin disease to extensive cutaneous 
plaque and tumor involvement to extracutaneous compartments of blood, 
lymph nodes, and viscera. advances in genomic technologies have enabled the 
increasing characterization of genetic alterations in this malignancy; using this 
technology, investigators hope to understand mF’s variable behavior and patho-
genesis. In this issue, Salgado et al. identify regions of genomic Dna alterations 
from 41 mF samples and report associations with prognosis.
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Clinical Implications
•  Epitope spreading is the sequential development of new antibodies against 
seemingly less accessible regions of target proteins in autoimmunity.
•  The identification of mechanisms of epitope spreading in the 
immunobullous diseases may lead to novel therapies that limit the process 
of spreading.
•  Because of accessibility, the analysis of epitope spreading in skin disease 
may provide insight into pathogenic mechanisms in systemic autoimmune 
diseases and transplantation immunity.
In recognition that cancer is fun-
damentally dependent on genetic 
alterations (Vogelstein and Kinzler, 
2004), the number of genomic 
